Remegen Co., Ltd.

This study tested an experimental drug called RC18 in 29 adults with systemic myasthenia gravis, a condition that causes muscle weakness. The goal was to see if RC18 is safe and can help control symptoms. Participants received the drug while continuing their usual treatments, and…

This phase 2 trial tested a biologic drug called RC18 in 42 people with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. Participants received weekly injections of either RC18 (at 160 mg or 240 mg) or a placebo for 24 weeks. The goal was to see if…

This early-stage study tested a drug called telitacicept in 16 children with lupus. The goal was to see how the drug moves through the body and if it helps control the disease. While not a cure, it may offer a new way to manage lupus symptoms in young patients.

This phase 2 trial tested a drug called RC108 in 29 people with advanced digestive system cancers that have a protein called c-Met. RC108 is an antibody-drug combination given through a vein. The study looked at how well the drug shrinks tumors and what side effects occur. Result…

This early-phase study tested a new drug called RC108-ADC in 67 people with advanced solid tumors that have a specific protein (c-Met). The drug is designed to deliver a toxin directly to cancer cells. The main goals were to check safety and find the best dose. Researchers also l…

This study tested a new drug called RC88 in 43 women with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum chemotherapy. The goal was to see if RC88 alone could shrink tumors and how safe it was. Participants had already tried at least three other…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at sid…

This study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.

This study tested a drug called telitacicept in 381 adults with active primary Sjogren's syndrome, an autoimmune disease causing dry eyes and mouth. Participants received either the drug or a placebo to see if it safely reduces disease activity. The goal is to control the conditi…